@article{ca450e0d4df1447a94c196d843f1c661,
title = "Repurposing quinacrine against Ebola virus infection in vivo",
abstract = "Quinacrine hydrochloride is a small-molecule, orally bioavailable drug that has been used clinically as an antimalarial and for many other applications. A machine learning model trained on Ebola virus (EBOV) screening data identified quinacrine as a potent (nanomolar) in vitro inhibitor. In the current study, quinacrine 25 mg/kg was shown to protect 70% of mice (statistically significant) from a lethal challenge with mouse-adapted EBOV with once-daily intraperitoneal dosing for 8 days.",
keywords = "Antiviral, Ebola virus, Ebola virus disease, Quinacrine",
author = "Lane, {Thomas R.} and Comer, {Jason E.} and Freiberg, {Alexander N.} and Madrid, {Peter B.} and Sean Ekins",
note = "Funding Information: We thank the technical staff at UTMB for performing the high containment studies, including Terry Juelich, Birte Kalveram, Shane Massey, David Perez, Jennifer Smith, Rose Wanjala, and Lihong Zhang. We gratefully acknowledge Dan Contoit and the team at Bioduro, as well as discussions with Mary Lingerfelt, Manu Anantpadma, Robert Davey, and Joel Freundlich. Mindy Davis is gratefully acknowledged for assistance with the NIAID virus screening capabilities (task order no. B22). This project has been funded in whole or in part by federal funds from the Division of Microbiology and Infectious Diseases, NIAID, National Institutes of Health (NIH), Department of Health and Human Services, under contract no. HHSN272201000040I, task order HHSN27200011 (UTMB primary investigator, David Beasley). We kindly acknowledge NIH funding from the National Center for Advancing Translational Sciences (R21TR001718, to S.E.). T.R.L. is an employee at Collaborations Pharmaceuticals, Inc. S.E. is the CEO of Collaborations Pharmaceuticals, Inc. Funding Information: This project has been funded in whole or in part by federal funds from the Division of Microbiology and Infectious Diseases, NIAID, National Institutes of Health (NIH), Department of Health and Human Services, under contract no. HHSN272201000040I, task order HHSN27200011 (UTMB primary investigator, David Beasley). We kindly acknowledge NIH funding from the National Center for Advancing Translational Sciences (R21TR001718, to S.E.). Publisher Copyright: Copyright {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved.",
year = "2019",
doi = "10.1128/AAC.01142-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",
}